Date:9/8/2009

ch and the expected impact of the acquisition on Cell Biosciences' strategic and operational plans and financial results, contain forward-looking statements that are subject to change. Statements including words such as "anticipate", "believe", "estimate" or "expect" and statements in the future tense are forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual events or actual future results to differ materially from the expectations set forth in the forward-looking statements. Some of the factors which could cause results to differ materially from the expectations expressed in these forward-looking statements include the following: the requirement that Alpha Innotech's stockholders must approve the transaction; the completion of Cell Biosciences' Series D Preferred Stock financing; the possibility that the transaction will not close or that the closing may be delayed; the effect of the announcement of the acquisition on Alpha Innotech's strategic relationships, operating results and business generally, including the ability to retain key employees and other factors described in Alpha Innotech's SEC filings (including Alpha Innotech's Annual Report on Form 10-K for the year ended December 31, 2008 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2009). If any of these risks or uncertainties materializes, the acquisition may not be consummated, the potential benefits of the acquisition may not be realized, Alpha Innotech's operating results and financial performance could suffer, and actual results could differ materially from the expectations described in these forward-looking statements. Neither Cell Biosciences nor Alpha Innotech assume any obligation to update these forward-looking statements.

Additional Information About the Proposed Transaction and Where You Can Find It

In connection with the proposed transaction, Alpha Innotech inten
'/>"/>

SOURCE Cell Biosciences, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
2. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
3. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
4. SABiosciences Ranked 17th on the Best Places to Work Industry Award for Biotech and Pharmaceutical Companies
5. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
6. Biosciences Firm Chooses CloudCraze for eCommerce Business Solution -- LI-COR and EDL Consulting Take Expertise into the "Cloud"
7. Cryo-Cell Announces Strategic Partnership With S-Evans Biosciences, Inc.
8. BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels
9. BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels
10. Ingenuitys Technology Powers BD Cell Pathways Tool on New BD Biosciences Website
11. YM BIOSCIENCES USA RECEIVES CLEARANCE FROM US TREASURY DEPARTMENT TO EXTEND CLINICAL PROGRAM FOR NIMOTUZUMAB